Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial

被引：0

作者：

Inzucchi, Silvio E. ^{[1
]}

Wanner, Christoph ^{[2
]}

Fitchett, David ^{[3
]}

Zinman, Bernard ^{[4
]}

Anker, Stefan D. ^{[5
,6
,7
]}

Pocock, Stuart J. ^{[8
]}

Mattheus, Michaela ^{[9
]}

Hantel, Stefan ^{[10
]}

机构：

[1] Yale Univ, Sch Med, Sect Endocrinol, New Haven, CT 06520 USA

[2] Wurzburg Univ Clin, Wurzburg, Germany

[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[4] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada

[5] German Ctr Cardiovasc Res DZHK Partner Site, Berlin Inst Hlth Ctr Regenerat Therapies BCRT, Dept Cardiol CVK, Berlin, Germany

[6] Charite Univ Med Berlin, Berlin, Germany

[7] Wroclaw Med Univ, Inst Heart Dis, Wroclaw, Poland

[8] London Sch Hyg & Trop Med, Dept Med Stat, London, England

[9] Boehringer Ingelheim Pharm GmbH & Co KG, Ingelheim, Germany

[10] Boehringer Ingelheim Pharm GmbH & Co KG, Biberach, Germany

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2024年 / 212卷

关键词：

Diabetes; Empagliflozin; Hospitalisation; SGLT2; inhibitors; Recurrent events; DAPAGLIFLOZIN; FAILURE; DISEASE;

D O I：

10.1016/j.diabres.2024.111715

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In EMPA-REG OUTCOME, empagliflozin reduced the composite of total events leading to/prolonging hospitalisation for any cause and all -cause mortality by 24 % versus placebo in patients with T2DM and ASCVD, with 67.7 events prevented/1000 patient -years and a low NNT. Effects were sustained and were consistent regardless of the reason for hospitalisation.

引用

页数：5

共 23 条

[1] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[2] Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT [J].

Bhatt, Deepak L. ;

Steg, Ph Gabriel ;

Miller, Michael ;

Brinton, Eliot A. ;

Jacobson, Terry A. ;

Ketchum, Steven B. ;

Doyle, Ralph T. ;

Juliano, Rebecca A. ;

Jiao, Lixia ;

Granowitz, Craig ;

Tardif, Jean-Claude ;

Gregson, John ;

Pocock, Stuart J. ;

Ballantyne, Christie M. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (22) :2791-2802

[3] Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis [J].

Cahn, Avivit ;

Melzer-Cohen, Cheli ;

Pollack, Rena ;

Chodick, Gabriel ;

Shalev, Varda .

DIABETES OBESITY & METABOLISM, 2019, 21 (02) :340-348

[4] Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials [J].

Claggett, Brian ;

Pocock, Stuart ;

Wei, L. J. ;

Pfeffer, Marc A. ;

McMurray, John J. V. ;

Solomon, Scott D. .

CIRCULATION, 2018, 138 (06) :570-577

[5] Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis [J].

Feng, Kent Y. ;

Li, JingWei ;

Ianus, Juliana ;

de Zeeuw, Dick ;

Fulcher, Greg R. ;

Pfeifer, Michael ;

Matthews, David R. ;

Jardine, Meg J. ;

Perkovic, Vlado ;

Neal, Bruce ;

Mahaffey, Kenneth W. .

DIABETES OBESITY & METABOLISM, 2021, 23 (12) :2707-2715

[6] Empagliflozin in Patients with Chronic Kidney Disease [J].

Herrington, William G. ;

Staplin, Natalie ;

Wanner, Christoph ;

Green, Jennifer B. ;

Hauske, Sibylle J. ;

Emberson, Jonathan R. ;

Preiss, David ;

Judge, Parminder ;

Mayne, Kaitlin J. ;

Ng, Sarah Y. A. ;

Sammons, Emily ;

Zhu, Doreen ;

Hill, Michael ;

Stevens, Will ;

Wallendszus, Karl ;

Brenner, Susanne ;

Cheung, Alfred K. ;

Liu, Zhi-Hong ;

Li, Jing ;

Hooi, Lai Seong ;

Liu, Wen ;

Kadowaki, Takashi ;

Nangaku, Masaomi ;

Levin, Adeera ;

Cherney, David ;

Maggioni, Aldo P. ;

Pontremoli, Roberto ;

Deo, Rajat ;

Goto, Shinya ;

Rossello, Xavier ;

Tuttle, Katherine R. ;

Steubl, Dominik ;

Petrini, Michaela ;

Massey, Dan ;

Eilbracht, Jens ;

Brueckmann, Martina ;

Landray, Martin J. ;

Baigent, Colin ;

Haynes, Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (02) :117-127

[7] Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population [J].

Li, Weijia ;

Katamreddy, Adarsh ;

Kataria, Rachna ;

Myerson, Merle L. ;

Taub, Cynthia C. .

DRUGS-REAL WORLD OUTCOMES, 2022, 9 (01) :53-62

[8]

McGuire DK, 2020, LANCET DIABETES ENDO, V8, P949, DOI 10.1016/S2213-8587(20)30344-2

[9] Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial [J].

Murphy, Sabina A. ;

Pedersen, Terje R. ;

Gaciong, Zbigniew A. ;

Ceska, Richard ;

Ezhov, Maiat, V ;

Connolly, Derek L. ;

Jukema, J. Wouter ;

Toth, Kalman ;

Tikkanen, Matti J. ;

Im, Kyungah ;

Wiviott, Stephen D. ;

Kurtz, Christopher E. ;

Honarpour, Narimon ;

Giugliano, Robert R. ;

Keech, Anthony C. ;

Sever, Peter S. ;

Sabatine, Marc S. .

JAMA CARDIOLOGY, 2019, 4 (07) :613-619

[10] Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study [J].

Nystrom, Thomas ;

Toresson Grip, Emilie ;

Gunnarsson, Joel ;

Casajust, Paula ;

Karlsdotter, Kristina ;

Skogsberg, Josefin ;

Ustyugova, Anastasia .

DIABETES OBESITY & METABOLISM, 2023, 25 (01) :261-271

← 1 2 3 →